Literature DB >> 10423234

X-ray structure of the Asn276Asp variant of the Escherichia coli TEM-1 beta-lactamase: direct observation of electrostatic modulation in resistance to inactivation by clavulanic acid.

P Swarén1, D Golemi, S Cabantous, A Bulychev, L Maveyraud, S Mobashery, J P Samama.   

Abstract

The clinical use of beta-lactam antibiotics combined with beta-lactamase inactivators, such as clavulanate, has resulted in selection of beta-lactamases that are insensitive to inactivation by these molecules. Therefore, therapeutic combinations of an enzyme inactivator and a penicillin are harmless for bacteria harboring such an enzyme. The TEM beta-lactamase variants are the most frequently encountered enzymes of this type, and presently, 20 variants are designated as inhibitor-resistant TEM ("IRT") enzymes. Three mutations appear to account for the phenotype of the majority of IRT enzymes, one of them being the Asn276Asp substitution. In this study, we have characterized the kinetic properties of the inhibition process of the wild-type TEM-1 beta-lactamase and of its Asn276Asp variant with the three clinically used inactivators, clavulanic acid (clavulanate), sulbactam, and tazobactam, and we report the X-ray structure for the mutant variant at 2.3 A resolution. The changes in kinetic parameters for the interactions of the inhibitors with the wild-type and the mutant enzymes were more pronounced for clavulanate, and relatively inconsequential for sulbactam and tazobactam. The structure of the Asn276Asp mutant enzyme revealed a significant movement of Asp276 and the formation of a salt bridge of its side chain with the guanidinium group of Arg244, the counterion of the inhibitor carboxylate. A water molecule critical for the inactivation chemistry by clavulanate, which is observed in the wild-type enzyme structure, is not present in the crystal structure of the mutant variant. Such structural changes favor the turnover process over the inactivation chemistry for clavulanate, with profound phenotypic consequences. The report herein represents the best studied example of inhibitor-resistant beta-lactamases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10423234     DOI: 10.1021/bi990758z

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  12 in total

1.  Mutant TEM beta-lactamase producing resistance to ceftazidime, ampicillins, and beta-lactamase inhibitors.

Authors:  Sergei Vakulenko; Dasantila Golemi
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

2.  Hydrolytic mechanism of OXA-58 enzyme, a carbapenem-hydrolyzing class D β-lactamase from Acinetobacter baumannii.

Authors:  Vidhu Verma; Sebastian A Testero; Kaveh Amini; William Wei; Jerome Liu; Naresh Balachandran; Tharseekan Monoharan; Siobhan Stynes; Lakshmi P Kotra; Dasantila Golemi-Kotra
Journal:  J Biol Chem       Date:  2011-08-31       Impact factor: 5.157

3.  TEM-80, a novel inhibitor-resistant beta-lactamase in a clinical isolate of Enterobacter cloacae.

Authors:  Corinne Arpin; Roger Labia; Véronique Dubois; Patrick Noury; Muriel Souquet; Claudine Quentin
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

4.  Structural consequences of the inhibitor-resistant Ser130Gly substitution in TEM beta-lactamase.

Authors:  Veena L Thomas; Dasantila Golemi-Kotra; Choonkeun Kim; Sergei B Vakulenko; Shahriar Mobashery; Brian K Shoichet
Journal:  Biochemistry       Date:  2005-07-05       Impact factor: 3.162

5.  Strategic design of an effective beta-lactamase inhibitor: LN-1-255, a 6-alkylidene-2'-substituted penicillin sulfone.

Authors:  Priyaranjan Pattanaik; Christopher R Bethel; Andrea M Hujer; Kristine M Hujer; Anne M Distler; Magdalena Taracila; Vernon E Anderson; Thomas R Fritsche; Ronald N Jones; Sundar Ram Reddy Pagadala; Focco van den Akker; John D Buynak; Robert A Bonomo
Journal:  J Biol Chem       Date:  2008-10-27       Impact factor: 5.157

6.  Why tazobactam and sulbactam have different intermediates population with SHV-1 β-lactamase: a molecular dynamics study.

Authors:  Rui Li; Yeng-Tseng Wang; Cheng-Lung Chen
Journal:  J Mol Model       Date:  2013-03-01       Impact factor: 1.810

7.  Substitutions at position 105 in SHV family β-lactamases decrease catalytic efficiency and cause inhibitor resistance.

Authors:  Mei Li; Benjamin C Conklin; Magdalena A Taracila; Rebecca A Hutton; Marion J Skalweit
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

8.  The role of a second-shell residue in modifying substrate and inhibitor interactions in the SHV beta-lactamase: a study of ambler position Asn276.

Authors:  Sarah M Drawz; Christopher R Bethel; Kristine M Hujer; Kelly N Hurless; Anne M Distler; Emilia Caselli; Fabio Prati; Robert A Bonomo
Journal:  Biochemistry       Date:  2009-06-02       Impact factor: 3.162

9.  Integration of a transposon Tn1-encoded inhibitor-resistant beta-lactamase gene, bla(TEM-67) from Proteus mirabilis, into the Escherichia coli chromosome.

Authors:  Thierry Naas; Marie Zerbib; Delphine Girlich; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

Review 10.  Three decades of beta-lactamase inhibitors.

Authors:  Sarah M Drawz; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.